The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RNAC | -59.43% | -78.82% | -26.69% | -72% |
| S&P | +14.5% | +93.32% | +14.09% | +49% |
Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides RNA cell therapies for the treatment of autoimmune diseases. The company is headquartered in Gaithersburg, MD.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.30M | -99.1% |
| Gross Profit | -$0.29M | -100.9% |
| Gross Margin | -97.65% | -197.1% |
| Market Cap | $269.67M | -43.9% |
| Market Cap / Employee | $7.10M | 0.0% |
| Employees | 38 | 0.0% |
| Net Income | $15.89M | 65.0% |
| EBITDA | -$21.22M | -246.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $160.32M | 83.8% |
| Accounts Receivable | $0.35M | -99.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $9.56M | -22.6% |
| Short Term Debt | $3.79M | 50.2% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -102.11% | 0.0% |
| Return On Invested Capital | -407.41% | -225.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$20.12M | -25.5% |
| Operating Free Cash Flow | -$17.52M | -21.3% |
| Metric | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -1.28 | -2.83 | 418.81 | -12.37 | 5072.56% |
| Price to Sales | 4.12 | 4.08 | 8.88 | 7.22 | - |
| Price to Tangible Book Value | -0.47 | -0.96 | -1.59 | -1.22 | 641.83% |
| Enterprise Value to EBITDA | 28.22 | -8.18 | -8.44 | -6.02 | 514.27% |
| Return on Equity | -938.4% | - | |||
| Total Debt | $14.87M | $14.65M | $14.07M | $13.35M | 27.66% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
